So-Young (SY) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
1.5B
Gross Profit
899.1M
61.30%
Operating Income
-84.5M
-5.76%
Net Income
-587.2M
-40.03%
EPS (Diluted)
-$5.72
Balance Sheet Metrics
Total Assets
2.7B
Total Liabilities
776.4M
Shareholders Equity
2.0B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
-669.8M
Free Cash Flow
-88.2M
Revenue & Profitability Trend
So-Young Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.5B | 1.3B | 1.7B | 1.3B |
| Cost of Goods Sold | 567.6M | 544.3M | 393.3M | 327.9M | 212.2M |
| Gross Profit | 899.1M | 953.7M | 864.6M | 1.4B | 1.1B |
| Operating Expenses | 983.6M | 1.0B | 967.4M | 1.3B | 1.1B |
| Operating Income | -84.5M | -61.0M | -102.8M | 33.3M | -56.7M |
| Pre-tax Income | -588.1M | 7.9M | -87.1M | -16.4M | 93.0K |
| Income Tax | -905.0K | -18.1M | -21.0M | 21.2M | -4.8M |
| Net Income | -587.2M | 25.9M | -66.1M | -37.6M | 4.9M |
| EPS (Diluted) | -$5.72 | $0.21 | -$0.61 | -$0.08 | $0.05 |
Income Statement Trend
So-Young Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.7B | 1.7B | 1.9B | 2.0B | 2.8B |
| Non-Current Assets | 1.0B | 1.5B | 1.3B | 1.3B | 496.0M |
| Total Assets | 2.7B | 3.2B | 3.2B | 3.3B | 3.3B |
| Liabilities | |||||
| Current Liabilities | 630.2M | 540.4M | 538.0M | 712.4M | 570.9M |
| Non-Current Liabilities | 146.2M | 112.8M | 52.0M | 100.9M | 101.6M |
| Total Liabilities | 776.4M | 653.3M | 590.0M | 813.3M | 672.4M |
| Equity | |||||
| Total Shareholders Equity | 2.0B | 2.6B | 2.6B | 2.5B | 2.6B |
Balance Sheet Composition
So-Young Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -587.2M | 25.9M | -66.1M | -37.6M | 4.9M |
| Operating Cash Flow | -669.8M | 17.7M | -89.2M | 52.3M | 92.7M |
| Investing Activities | |||||
| Capital Expenditures | -62.5M | -50.9M | -15.6M | -44.9M | -37.0M |
| Investing Cash Flow | 257.0M | -202.6M | -572.2M | 339.8M | 123.8M |
| Financing Activities | |||||
| Dividends Paid | -43.6M | - | - | - | - |
| Financing Cash Flow | -91.8M | -100.2M | -14.5M | -217.7M | -13.0M |
| Free Cash Flow | -88.2M | -28.7M | -128.6M | 39.2M | 142.2M |
Cash Flow Trend
So-Young Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
17.18
Forward P/E
40.70
Price to Book
0.23
Price to Sales
0.28
PEG Ratio
40.70
Profitability Ratios
Profit Margin
-41.60%
Operating Margin
-14.60%
Return on Equity
-27.13%
Return on Assets
-1.95%
Financial Health
Current Ratio
2.75
Debt to Equity
13.01
Beta
1.01
Per Share Data
EPS (TTM)
-$0.81
Book Value per Share
$17.77
Revenue per Share
$14.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| sy | 407.9M | 17.18 | 0.23 | -27.13% | -41.60% | 13.01 |
| Veeva Systems | 46.5B | 60.25 | 7.46 | 14.06% | 27.34% | 1.24 |
| Ge Healthcare | 34.7B | 15.94 | 3.78 | 26.44% | 11.03% | 97.52 |
| Premier | 1.9B | 21.25 | 1.17 | 6.85% | 4.96% | 19.35 |
| Certara | 1.8B | 104.00 | 1.70 | -0.25% | -0.67% | 28.51 |
| GoodRx Holdings | 1.7B | 69.57 | 2.68 | 4.43% | 3.57% | 82.71 |
Financial data is updated regularly. All figures are in the company's reporting currency.